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Background: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) comprise
a heterogeneous disease group. Factors that affect long-term survival remain uncertain.
Complete population-representative cohorts with long-term follow-up are scarce.
Aim: To evaluate factors of importance for the long-term survival.
Methods and results: An Observational population-based study on consecutive GEP-
NEN patients diagnosed from 2003 to 2013, managed according to national guidelines.
Univariable and multivariable survival analyses were performed to evaluate overall sur-
vival (OS) and to identify independent prognostic factors. One hundred ninety eligible
patients (males, 58.9%) (median age, 60.0 years; range, 10.0–94.2 years) were included.
The small bowel, appendix, and pancreas were the most common tumor locations. The
World Health Organization (WHO) tumor grade 1–3 distributions varied according to
the primary location and disease stage. Primary surgery with curative intent was per-
formed in 66% of the patients. The median OS of the study population was 183 months
with 5- and 10-year OS rates of 66% and 57%, respectively. Only age, WHO tumor
grade, and primary surgical treatment were independent prognostic factors for OS.
Conclusion: The outcomes of GEP-NEN patients are related to several factors includ-
ing age and primary surgical treatment. WHO tumor grading, based on the
established criteria, should be routine in clinical practice. This may improve clinical
decision-making and allow the comparison of outcomes among different centers.
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1 | INTRODUCTION
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are
neuroendocrine tumors characterized by heterogeneous clinical
patterns, a relatively indolent growth rate, and the ability to secrete
peptide hormones and biogenic amines.1-3 Historically, GEP-NENs
were thought to be relatively rare, but recent reports from different
regions suggest a higher and increasing annual GEP-NEN incidence.3-7
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Many patients with well-differentiated neuroendocrine neoplasms,
even those with advanced disease at the time of diagnosis, can sur-
vive for several years.5,8-10 In terms of the prevalence in this group of
patients, GEP-NENs are the most common gastrointestinal malig-
nancy after colorectal cancer.1 This translates into a considerable
number of patients requiring long-term surveillance and treatment.
An enhanced understanding of the biology of this disease and the
development of novel diagnostic approaches (i.e., molecular detection,
receptor-based approaches, and metabolic positron emission tomog-
raphy [PET]) and treatment options (i.e., biological or targeted treat-
ments and improved surgical approaches) have increased the
complexity of the clinical management of neuroendocrine tumors.3,11
Some of these efforts have likely contributed to an improved survival
rate of subgroups of GEP-NEN patients.5,8
This study aimed to evaluate the long-term survival in a
population-based cohort of consecutive GEP-NEN patients treated in
routine practice who were classified according to current grading and
staging criteria of the given time period.12,13
2 | MATERIALS AND METHODS
This observational study included all GEP-NEN patients treated at a
single hospital that covers a geographically well-defined area. The
manuscript follows the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement.14
2.1 | Study population
The study population comprised unselected consecutive patients with
GEP-NENs diagnosed at the Stavanger University Hospital between
2003 and 2013, as reported previously in greater detail.4 This is the
only hospital that serves a regional area of approximately 380 000
inhabitants; thus, patients consisted of a population-representative
cohort from the Norwegian southwest coast and a mixed urban-
rural area.
We excluded nine patients with an unknown primary tumor loca-
tion. Moreover, three patients with esophageal and two patients with
bile duct primary tumors were excluded due to small sample sizes.
This study does not include mixed neuroendocrine neoplasm
(MINEN). Also, Goblet cell carcinoma as a specifically defined entity
was not included. Thus, the final study population included 190 con-
secutive patients.
2.2 | Clinical workup for primary treatment
decision-making
Routine evaluation of patients encompassed clinical examination, neces-
sary blood tests including tumor marker detection (i.e., chromogranin A
[CgA]), and standard oncologic imaging (i.e., multiphase computed
tomography [CT], magnetic resonance imaging [MRI], and somatostatin
receptor-scintigraphy [SRS]), as described in available guidelines.15-18
Positron emission tomography (PET) imaging (68Ga-DOTA-somatostatin
analog-PET/CT) and metabolic PET-imaging were not routinely per-
formed. Transthoracic echocardiography was used for suspected carci-
noid heart disease. Endoscopy, including endoscopic ultrasound (EUS)
and video capsule endoscopy, were available if indicated. Diagnostic step
sequences and appropriate adjustments were made according to the clin-
ical presentation, for example, in symptomatic patients, adequate diag-
nostic steps were performed to locate the primary tumor and to evaluate
the disease stage. In contrast, if a gastroenteropancreatic neuroendocrine
tumor (GEP-NET) was incidentally discovered during surgery for a tenta-
tive diagnosis (i.e., indication for surgery) other than GEP-NET,
a postoperative evaluation was performed.
2.3 | Classification and staging according to
morphology
As previously described,4 patients were originally staged according to
the 2009 Union for International Cancer Control (UICC) Tumor-Node-
Metastasis (TNM) classification,12 and the primary tumors were
graded according to the 2010 World Health Organization (WHO) clas-
sification.13 In the present study, the most current criteria19 (Table 1)
were applied by two pathologists (D.L. and E.G.) during the indepen-
dent re-grading of the tumors and included the novel distinction
between grade 3 neuroendocrine tumors (NET) and grade 3 neuroen-
docrine carcinomas (NEC).
2.4 | Primary surgical treatment and treatments
for advanced disease
Surgical resection of the primary tumor with curative intent was per-
formed whenever possible. During the entire study period, we
embraced the strategy of removing a primary small intestinal NET,
TABLE 1 The World Health Organization (WHO) 2010
classification of gastroenteropancreatic neoplasia, grades G1-G3
Mitoses
(per 10 HPFs) Ki-67 index
Neuroendocrine tumor
Grade 1 <2 ≤2a
Grade 2 2–20 3–20
Neuroendocrine carcinoma
Grade 3 – large-cell or small-cell type >20 >20
Mixed adenoneuroendocrine carcinoma
Hyperplastic and preneoplastic lesions
Abbreviation: HPF, high-power field.
Note: At least 50 HPFs were counted (2 mm2, original magnification x40).
Ki-67 immunoreactivity evaluated in “hot spots.”
aENETS20 recommends that ≤2 should be replaced by <3 to include
decimal numbers between 2 and 3.
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even in cases of confirmed unresectable liver metastasis.21,22 More-
over, palliative surgical treatment was considered when it was feasible
to relieve symptoms due to tumor obstruction or a tumor mass or to
relieve uncontrolled clinical symptoms due to a functional tumor.
Symptom- and disease-oriented systemic treatments were
offered to patients diagnosed with advanced disease, and biological
therapy with long-acting somatostatin analogs (e.g., octreotide and
lanreotide) and interferon α-2B (IFN) were given for well-
differentiated tumors. In contrast, patients with poorly differentiated
carcinomatous neuroendocrine carcinomas were offered chemother-
apy with various cytotoxic agents in line with principles provided else-
where.17,18,23,24 Liver metastasis-directed therapies (i.e., hepatic
arterial embolization (HAE), radiofrequency ablation (RFA), cyto-
reductive surgical resection), and peptide receptor radionuclide ther-
apy (PRRT) were offered when indicated. Newer drugs that have been
routinely available for more than a decade, such as oral tyrosine
kinase inhibitors (sunitinib) and everolimus, or novel combinations of
cytotoxic agents (platinum or etoposide-based therapies, combination
therapies with folinic acid, 5-fluorouracil [5-FU] or irinotecan
[FOLFIRI] or FOLFIRI combined with oxaliplatin [i.e., FOLFIRINOX]),
were discussed by a multidisciplinary team and administered in line
with current scientific recommendations.24
2.5 | Follow-up
Follow-up was conducted by clinical specialists (i.e., primarily sur-
geons, oncologists, and gastroenterologists) with a particular interest
in treating GEP-NENs. Follow-up visits were scheduled and com-
pleted at the hospital outpatient clinics. Some patients with minimal
risk of relapse or those who were radically treated (e.g., surgically
treated patients with an incidentally diagnosed tiny appendiceal neu-
roendocrine tumor of low grade [WHO grade 1] with tumor-free mar-
gins) did not complete scheduled follow-up in agreement with the
Nordic guidelines.17,24 The follow-up visits included clinical screening
for any (new) symptoms and a physical examination supplemented by
cross-sectional imaging (mostly computed tomography [CT] with
intravenous contrast, MRI or SRS), standard blood biochemistry analy-
sis, and measurement of chromogranin A (CgA) as a tumor biomarker,
as previously suggested.23 Additional examinations or imaging were
performed as indicated. The frequency and components of outpatient
visits varied according to the grade of the primary tumor, disease
stage, treatment intent, and presence of any suspicious signs of
metachronous disease progression, in line with recommendations pro-
vided by the Norwegian Neuroendocrine Tumor Group (NNTG)18 and
international recommendations.17,23,25
Any new patient diagnosed with a GEP-NEN or any patient with
relapse or disease progression encountered during follow-up was
assessed by a multidisciplinary team (MDT) to enable decision-making
according to current guidelines. Thus, various treatments were admin-
istered to patients with confirmed relapse or those with progressive
disease who were receiving systemic therapy for advanced disease.
The type of treatments, sequences, combinations, and durations were
adjusted according to treatment responses or disease progression
according to current treatment principles. Patients in need of treat-
ment options not available at the hospital (e.g., peptide receptor radio-
nuclide therapy [PRRT]) at the time were referred to cooperating
centers in Sweden or Denmark.
The management of patients was guided by national and
European guidelines, and specifically, the most recent Nordic guide-
lines for the management of GEP-NENs (201017 or 201424).
Time and cause of death were obtained from hospital records,
which are electronically linked to the Governmental Statistics Norway
database (www.ssb.no). Complete follow-up of all patients was
achieved.
2.6 | Assessment of survival
Overall survival (OS) was defined as the number of months from the
date of diagnosis to the date of death from any cause or the date of
the last follow-up (May 1, 2020) in surviving patients. Confirmed
death due to advanced GEP-NET was considered an endpoint when
the disease-specific survival (DSS) was calculated.
Relative survival was calculated as the proportion of patients who
survived to a given postoperative time divided by the proportion of
individuals of the same age, sex, and year of birth in the general popu-
lation that would survive to that time. Population survival was calcu-
lated using Norwegian population lifetime tables from the Human
Mortality Database (HMD, http://www.mortality.org/).
2.7 | Statistics
The statistical calculations were performed using SPSS version 25 for
Mac (IBM, Armonk, NY) and R 3.6.3.26 The R-package “relsurv” ver-
sion 2.2-3 was used for the relative survival calculation.27
In the descriptive analyses, categorical data are reported as num-
bers and percentages, and continuous data are reported as medians
and ranges or interquartile ranges (IQRs). Non-parametric tests were
used for comparisons between subgroups. OS was estimated by the
Kaplan-Meier method, and the log-rank test evaluated differences
between subgroups. Cox proportional hazard analyses were per-
formed to assess independent predictive factors of OS and DSS. Fac-
tors with a p-value < .2 in the univariable analysis were included in the
multivariable models, and these selections were run with a backward
stepwise model. The results of the Cox regression analyses are
expressed as hazard ratios (HRs) with 95% confidence intervals (CIs).
All tests were two-sided, and a p-value < .050 was considered
statistically significant.
3 | RESULTS
Of 204 patients, 190 (93.1%) patients with a median age of 60.0
(range, 10.0–94.2) years who were diagnosed with GEP-NENs
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between 2003 and 2013, were eligible for further evaluation. The
clinical characteristics of the study population and the descriptions of
GEP-NENs are provided in Table 2. Small bowel tumors were primarily
localized in the ileum. Among the 33 patients with pancreatic NEN,
four patients had clinically functional insulinomas.
While males showed a slight predominance of 58.9%, no signifi-
cant differences were observed between sexes in the distribution of
the primary tumor location. However, in patients whose primary
tumors were in the appendix, the median age of 30.4 (range, 10.0–
84.9) years was significantly lower than the median age of 62.5 (range,
19.5–90.5) years in patients whose primary tumors were in other
locations (p < .001).
Disease characteristics are displayed as WHO tumor grades 1–3
according to the primary tumor location in Figure 1 and UICC disease
stage in Figure 2(A). After the re-grading of tumors, 179 patients
(94.2%) had the same tumor grade. Moreover, nine (4.7%) tumors pre-
viously classified as grade 1 became grade 2, and eight (4.2%) tumors
previously classified as grade 2 were categorized as grade 1 tumors.
All grade 3 tumors remained unchanged.
Grade 2/3 primary tumors were more often found in the colon,
pancreas, or stomach. A larger proportion of grade 2/3 tumors was
found in patients diagnosed with stage III and IV disease. Of the
42 patients with grade 3 tumors, 7 (16.7%) patients had well-
differentiated NET G3 tumors (i.e., pancreas n = 3, colon n = 2, small
bowel n = 1, and unknown primary location n = 1), and the remaining
35 patients had neuroendocrine carcinomas (NEC). A small-cell tumor
type (SCNEC) was found in 14 (40%), while the remaining were large-
cell type (LCNEC) neuroendocrine carcinomas.
At the time of diagnosis, resection was performed in 150 patients
(78.9%), and of those, 66.3% (126/150) underwent surgery with cura-
tive intent (i.e., R0-resection with tumor-free margins). Curative sur-
gery was most frequently performed in patients with tumors in the
appendix, small bowel, pancreas, and rectum. However, tumors of
small bowel origin occurred in a large proportion of patients who
underwent palliative or debulking surgery. Due to advanced disease
or comorbidities. The remaining 40 patients (21.1%) did not undergo
surgery, and small bowel, colon, and pancreas NENs were commonly
observed in this group of patients (Table 2). Causes for not having sur-
gery were explained by advanced disease in 57.5% (23/40) of the
patients, and patient related factors (i.e., mostly significant comorbid-
ity) were decisive for 13 (32.5%) patients. An unknown cause was
encountered in 4 (10%) patients. No significant differences (p = .147)
were observed between genders with regard to causes for not having
primary surgery.
TABLE 2 Patients (n = 190) and disease characteristics according to primary treatment approach
Primary surgery with




surgery, n (%) p-value
Total 126 (66.3) 24 (12.6) 40 (21.1)
Median age (range), years 55.5 (10.0–90.5) 62.1 (48.0–82.2) 71.9 (48.5–94.2) <.001
Males (112, 58.9%): Females (78, 41.1%)
= 1.44:1
1.33:1 1.18:1 2.07:1 .448
Primary tumor location <.001
Stomach (n = 11) 5 (4.0) 1 (4.2) 5 (12.5)
Duodenum (n = 5) 1 (0.8) 1 (4.2) 3 (7.5)
Small bowel (n = 60) 36 (28.6) 15 (62.5) 9 (22.5)
Appendix (n = 48) 47 (37.3) 0 1 (2.5)
Colon (n = 15) 5 (4.0) 4 (16.7) 6 (15.0)
Rectum (n = 18) 15 (11.9) 1 (4.2) 2 (5.0)
Pancreas (n = 33) 17 (42.4) 2 (8.3) 14 (35.0)
UICC stage <.001
I 70 (55.6) 1 (4.3) 6 (15.0)
II 15 (11.9) 1 (4.3) 0
III 33 (26.2) 0 4 (10.0)
IV 8 (6.3) 21 (93.4) 30 (75.0)
WHO grade 1–3 <.001
G1 87 (69.0) 12(50.0) 10 (25.5)
G2 30 (23.8) 6 (25.0) 8 (20.0)
G3 9 (7.1) 7 (28.0) 17 (42.5)
Unknown 0 0 5 (12.5)
30-d mortality 3 (2.4) 2 (8.3) 5 (12.5) .106
90-d mortality 8 (6.4) 4 (16.7) 9 (22.5) .031
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Surgical treatment according to the UICC disease stage is shown
in Figure 2(B), and primary surgery was performed significantly more
often in patients with stage I–III disease than in patients with stage IV
disease (p < .001).
The 30-days mortality varied among treatment groups, with the
lowest mortality of 2.4% observed in patients who underwent surgery
with curative intent (Table 2). Although the early mortality was higher
after palliative surgery and highest when no primary surgery could be
performed, these differences did not reach statistical significance.
In contrast, the 90-days mortality was significantly different
among groups (p = .031), with threefold increased mortality (16.7%)
in patients who underwent palliative surgery. Patients who did not
undergo surgery had a fourfold higher mortality rate (22.5%) than
patients treated with curative intent (a 90-day mortality rate of 6.4%)
(Table 2).
As a part of primary treatment, 33 (17.4%) patients received bio-
logical treatments (i.e., somatostatin analogs), and 21 (11.1%) patients
received systemic chemotherapy. Moreover, several additional thera-
pies (i.e., HAE, targeted therapy, or PRRT-treatment) were adminis-
tered in some patients. Single or sequentially administered
treatments, sometimes in combination, were used as indicated and
were guided by current recommendations and based on a multi-
disciplinary clinical evaluation of the individual patient. However, no
meaningful comparison of survival according to treatment regimen
could be performed due to the variations in and many combinations
of the non-surgical treatments administered over the course of dis-
ease in this study population.
The median follow-up time was 82 (IQR, 20–117) months. Over-
all, 111 patients (111/190 = 58.4%) were still alive, and 88 of those
patients (88/111 = 79.3%) exhibited no evidence of disease at the
last follow-up. Among the 77 (77/190 = 40.6%) patients who died
during follow-up, advanced GEP-NEN malignant disease was deter-
mined as the cause of death in 57 (57/77 = 74.0%) patients. The
remaining 20 patients (26.0%) died from various unrelated causes.
The median OS time was 183 (95% CI 122–243) months with
5- and 10-year OS rates of 66% and 57%, respectively (Figure 3(A)).
Survival was significantly better in patients who underwent primary
surgery at the time of diagnosis (p < .001) (Figure 3(B)). Moreover,
tumor grade was significantly associated with OS, and a poor prognosis
was seen in those with WHO grade 3 tumors (p < .001) (Figure 3(C)). In
the univariable survival analysis, primary tumor location was statistically
significant (p < .001), as better survival was observed in patients with
tumors in the appendix, duodenum, or rectum, while worse survival
was observed in patients with primary colon tumors (Figure 3(D)).
As shown in Table 2, survival was similar in both sexes (p = .381). How-
ever, younger patients (i.e., median age ≤ 60 years) had significantly
better OS (p < .001) than those above 60 years of age, and patients
with incidentally discovered tumors had better survival (p = .003) than
symptomatic patients. In addition, survival differed significantly
(p < .001) among UICC stages, and a poor prognosis was observed in
stage IV patients.
In the Cox multivariable survival analysis, only age, WHO tumor
grade, and primary surgical treatment were independent predictors of
survival (Table 3). Regarding tumor grade as a prognostic factor, a
F IGURE 1 Distribution of
WHO tumor grades 1–3
according to primary tumor
localization
F IGURE 2 (A) Distribution of WHO tumor grades 1–3 according
to disease stage (I–IV). (B) Variations in primary surgical treatment by
disease stage (I–IV)
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significant difference was evident between those with malignant
grade 3 tumors and those with differentiated grade 1 and 2 tumors
(Table 3).
DSS rates of 73.1% and 68.1% were observed at 5 and 10 years,
respectively. A median DSS was not calculated for the whole cohort.
During the follow-up, 57 patients (30.0%) died from proven advanced
GEP-NEN disease, and the best DSS was observed in patients with
appendiceal and duodenal NENs; this was in contrast to a relatively
dismal prognosis in patients with colon-NENs, as indicated by the OS
in Figure 3(D). Intermediate survival was achieved in patients whose
primary tumors were located in the rectum, small intestine, stomach,
and pancreas, and a better DSS was observed in patients with tumors
of rectal and small intestinal origins. Notably, even patients with
pancreatic-NENs had at least a 50% median survival at 10 years.
In Figure 4, the estimated OS (Kaplan-Meier plot) is depicted
alongside the calculated relative survival curve for age and sex-
adjusted populations without a diagnosis of GEP-NENs. The curves
are relatively comparable during the first 2 years. After that, the rela-
tive survival curve plateaued, which shows that the excess deaths
attributed to the disease mainly occurred during the first 2 years.
4 | DISCUSSION
GEP-NENs comprise a heterogeneous group of tumors.1,3 Many fac-
tors including age, symptomatic disease, primary tumor location, dis-
ease stage, tumor grade, and primary surgical treatment are relevant
for prognostic prediction.6,8,10,28,29
In this study, the most common tumor origins were the small
intestine (31.6%), appendix (25.3%), and pancreas (17.4%). This is in
agreement with a Canadian population-based study, which indicated
the small bowel as the predominant location, although pancreas NENs
were not included in that report.30 In a recent national survey from
Iceland that studied a national population comparable to our hospital's
F IGURE 3 Overall survival (OS) with 95% CI (panel A) grouped according to whether primary surgery was performed or not (panel B) base on
WHO tumor grades 1–3 (panel C) and on localization of the primary neuroendocrine tumor (panel D)
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TABLE 3 (A) Factors of importance for overall survival (OS) (B) disease-specific survival (DSS)
(A)
Variable
Univariable analysis Multivariable analysis
p-value Hazard ratio (95%CI) p-value Hazard ratio (95%CI)
Gender .538 1.15 (0.73–1.82)
Age ≤ 60/>60 <.001 5.91 (3.39–10.29)
Age, continuous <.001 1.06 (1.05–1.08) <.001 1.06 (1.0–1.08)
Symptomatic .001 2.62 (1.51–4.55)
Primary tumor location <.001
Stomach Ref
Duodenum .295 0.32 (0.04–2.69)
Small bowel .647 0.81 (0.34–1.97)
Appendix .002 0.18 (0.06–0.53)
Colon .021 3.15 (1.19–8.37)
Rectum .154 0.43 (0.13–1.38)
Pancreas .874 0.93 (0.37–2.34)
WHO grade 1–3 <.001 <.001
Grade 1 Ref Ref
Grade 2 .009 2.19 (1.22–3.94.) .111 1.62 (0.90–2.91)
Grade 3 <.001 12.2 (7.0–21.5) <.001 8.32 (4.56–15.21)
Primary surgical treatment <.001 0.20 (0.12–0.31) <.001 0.43 (0.26–0.73)
UICC stage I–IV <.001
Stage I Ref
Stage II .003 3.92 (1.58–9.74)
Stage III .001 3.60 (1.67–7.77)
Stage IV <.001 8.71 (4.45–17.0)
(B)
Variable
Univariable analysis Multivariable analysis
p-value Hazard ratio (95%CI) p-value Hazard ratio (95%CI)
Gender .769 0.93 (0.55–1.56)
Age ≤ 60/>60 <.001 4.36 (2.38–7.99)
Age, continuous <.001 1.05 (1.03–1.07) <.001 1.04(1.02–1.06)
Symptomatic <.001 8.36 (3.02–23.11)
Primary tumor location <.001
Stomach Ref
Duodenum .967 1 (0–155)
Small bowel .350 0.63 (0.23–1.67)
Appendix .002 0.033 (0.004–0.28)
Colon .030 3.19 (1.12–9.11)
Rectum .179 0.41 (0.11–1.51)
Pancreas .920 0.95 (0.35–2.59)
WHO grade 1–3 <.001 <.001
Grade 1 Ref Ref
Grade 2 <.001 4.82 (2.13–10.91) .002 3.67 (1.62–8.33)
Grade 3 <.001 32.1 (14.7–70.0) <.001 22.2 (9.8–50.4)
Primary surgical treatment <.001 0.14 (0.08–0.24) <.001 0.32 (0.18–0.58)
UICC stage I–IV <.001
(Continues)
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regional population (i.e., ≈380 000), the tumor origin distribution was
slightly different, with 23.1% occurring in the small bowel, 30.8% in
the appendix, and 9.6% in the pancreas.6 These authors reported an
incidence of 3.85/100 000 from 2000 to 2014, which is lower than
the incidence of 5.83/100 000 reported in our previous study4 and by
others5 during a similar time period.
The relative indolent nature of this group of tumors is reflected in
a promising long-term prognosis, with 5- and 10-year DSS rates of
73.1% and 68.1%, respectively, and 5- and 10-year OS rates of 66%
and 57%, respectively. However, as shown in this study, survival is
related to several factors many of which cannot be moderated. More-
over, the increasing gap (see Figure 4) between the OS curve and the
calculated relative survival curve, particularly during the first 2 years,
may indicate that an excess mortality risk in GEP-NEN patients com-
pared with the age- and gender-adjusted general population, is mainly
attributed to the early time period after a GEP-NEN diagnosis is
confirmed.
Decreased survival has been associated with older age, the pres-
ence of symptoms, primary tumor location, tumor grade, and disease
stage.6,8,10 This study confirms the prognostic value of age for both
OS and DSS, with a 4- to 5-fold increased risk of death in patients
older than 60 years (i.e., median age). While survival also varied
according to primary tumor location, only the appendix (with an excel-
lent prognosis) and colon (with a more dismal prognosis) sites were
significantly associated with prognosis. However, the primary tumor
location did not retain its independent association with prognosis in
the multivariable analysis, which was also the case for the disease
stage. This is partly in contrast to recent population-based studies,5,8
which reported that sex, tumor differentiation, stage, and primary site
were independent predictors of OS. However, attention should be
paid to the differences among these studies, as they included patient
populations with tumor locations outside the gastrointestinal-
pancreatic sites, contained reporting bias due to a national registry,
and considered different definitions to describe tumor differentiation.
Thus, caution is warranted when making direct comparisons.
The prognostic relevance of tumor grading, as first proposed in
Europe more than a decade ago31 and eventually embraced by clini-
cians worldwide,32-34 is also supported by observations in this study.
As shown in our research, the distribution of grades varied according
to primary tumor site (Figure 1) and disease stage (Figure 2(A)), which
is in accordance with observations reported by Fitzgerald et al.35
based on the evaluation of 39 454 GEP-NEN patients from the
National Cancer Data Base (NCDB) in the US. However, the NCDB
does not report Ki67 staining-based grades, which is important to reli-
ably define tumor grade, as noted by the authors.35 Several limita-
tions, including inconsistent criteria for tumor grading and tumor
differentiation, and the fact that only malignant tumors are reported
in the registry, hinder the utility of the results provided in national
databases and registries.6,8,35
As seen in our study, NENs in the stomach, colon, and pancreas
were more often grade 2/3 tumors, and grade 2/3 tumors were
encountered more frequently in stage III/IV patients compared with
stage I/II patients. In the multivariable analysis, tumor grade was an
independent predictor of prognosis, unlike both primary tumor site
and disease stage. Recently, the WHO tumor grade (1–3) has gained
additional attention and is currently a standard part of the primary
evaluation of GEP-NEN patients.20 Moreover, the finding of a higher
grade (i.e., WHO grade 3) in metachronous liver metastases in GEP-
NEN patients compared with a low-grade primary tumor will further




Univariable analysis Multivariable analysis
p-value Hazard ratio (95%CI) p-value Hazard ratio (95%CI)
Stage I Ref
Stage II .022 8.08 (1.35–48.4)
Stage III .002 10.9 (2.35–50.3)
Stage IV <.001 44.7 (10.8–185)
Note: Bold letters in the Table to emphasise p-values that are statistically significant (e.g. p < 0.001 vs p = 0.47).
F IGURE 4 Overall survival (OS) and relative survival of the
patient cohort. Notably, the two curves have a similar pattern,
particularly during the early time period of 2–3 years
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Tumor grade not only serves as a prognostic factor but may also
serve as a predictive factor for the selection of GEP-NEN patients for
chemotherapy treatment,34 particularly in cases with a well-
differentiated morphology despite a high Ki67 index (>55%).38
In line with long-standing treatment principles, surgical treatment
was used whenever feasible.10,21,22,39 The high proportion of patients
(78.9%) who were surgically treated, including 66.3% treated with
curative intent in the total cohort, is partially explained by the
assumption that removal of the primary tumor even in stage IV
patients may be beneficial.40 The decision to operate on an individual
patient is based on many aspects, including patient- and disease-
related factors. In recent years, patients undergoing curative or
debulking surgery have undergone preoperative 68Ga DOTATOC-
PET/CT or 18FDG-PET/CT according to tumor grade. Studies have
demonstrated the superior sensitivity of SRI-PET in the detection of
metastasis and primary tumors and in the evaluation of disease bur-
den, and this methodology can have a significant impact on patient
management.41-44 This may improve the OS of patients undergoing
surgery due to more accurate preoperative staging.
Selection bias is likely to occur when surgically treated and non-
surgically treated patients are compared. Moreover, arguments for a
liberal approach to surgery are mostly based on retrospective obser-
vational studies, and no randomized prospective study has shed light
on this topic thus far. Several recent studies have promoted removal
of the primary tumor and claim that this strategy is beneficial to most
patients with GEP-NENs.40,45-47 An aggressive approach is suggested
for patients with several liver metastases to achieve >70% cyto-
reduction, which may translate into long-term survival.48 In contrast, a
watch-and-wait approach is considered for other patients, including
stage IV patients with small intestinal NENs49 and those with WHO
grade 1 non-functional pancreatic-NETs smaller than 2 cm.50 In addi-
tion, the recommended non-surgical approach may be replaced by
proton pump inhibitor (PPI) treatment in most MEN-1 patients with a
gastrinoma smaller than 2 cm.51
One strength of this study is that it provides observations from a
population-based patient cohort, with patients diagnosed and treated
consecutively and consistently according to previously described
guidelines and criteria.4 Both the clinical and morphological diagnoses
and workup were consistently completed during the study period
according to recommended national and international guidelines and
criteria and were managed using a multidisciplinary team approach. A
relatively long follow-up time with a median of almost 7 years, com-
plete follow-up regarding outcomes, and no missing prognostic factor
data included in the evaluation added to the strength of this observa-
tional study.
Some limitations of this study, including its retrospective nature,
should be mentioned. Due to the relatively low incidence of GEP-
NENs, the number of patients was limited. As already noted, due to
the heterogeneity of these patients and the variations in treatment
regimens, evaluations are challenging. However, this may partly be
remedied in that during the last decade, the universal criteria for UICC
staging12,13 and tumor grading13,52 have been implemented in routine
practice, which allows for more feasible and useful comparisons
between various studies. This study population mirrors largely a
population-based unselected population, with a very low number of
patients (n = 14) excluded from the final evaluation due to criteria
explained previously. Likely, this selection bias would hardly impact
any main conclusions drawn from this study.
Furthermore, we fully recognize the inherent risk of misinterpreta-
tions by comparing small subgroups based on underpowered calculations.
This study confirms the heterogeneity of patients with GEP-
NENs in both localization and stage but also in the aggressiveness of
the disease. Although many factors are associated with prognosis,
only age, tumor grade, and primary surgical treatment showed inde-
pendent prognostic importance for OS and DSS. However, these fac-
tors and endpoints are rather crude measures. To further tailor
treatment approaches to individual patients in terms of stage and type
of disease, novel insights beyond established clinical patterns and
morphological criteria are warranted. In this regard, recent observa-
tions that even pathologically homogeneous tumors, such as small
intestinal NENs, can be further subdivided into two different subtypes
of tumors are interesting.53 Moreover, the application of observed
epigenetic modifications to serve as potential prognostic biomarkers,
or even as therapeutic targets, may present novel opportunities in the
future.54 In addition, metabolic grading using FDG-PET55 and
the development of artificial intelligence (AI) imaging approaches
(i.e., tumor heterogeneity) seem to be promising prognostic stratifica-
tion tools.56 Finally, knowledge-based supportive care for GEP-NEN
patients, including those with a lengthy course trajectory, and even
those with advanced disease, should not be overlooked.57
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